Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 14c
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $240.54 -0.38%
EPS Growth %: -20.4%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -20.4%
Financial Fact:
Net income (loss): 87.15M
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.44, $0.14 better than the analyst estimate of $2.30. Revenue for the quarter came in at $328.1 million versus the consensus estimate of $319.74 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
- AutoZone beats profit view but misses on revenue
- FactSet acquires BCC Group to expand real-time market data platform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
